Antimicrobial peptides (AMPs) are small, amphipathic molecules that interact with bacterial membranes, leading to membrane disruption and cell death. They are naturally produced in various organisms and play a crucial role in innate immunity. Despite their potential as antibiotics, few AMPs have reached the market due to stability and toxicity issues. This article reviews the development and clinical trials of AMPs, their therapeutic market, and modifications to improve their stability and bioavailability. The global growth of antibiotic resistance has driven research into new antimicrobial therapies, including AMPs. The article discusses the challenges and strategies for clinical application, such as resistance, chemical modifications, and toxicity. Despite these challenges, the interest in AMPs remains high due to their effectiveness against multi-resistant pathogens. The focus is now on improving their "druggability" through modifications and delivery systems.Antimicrobial peptides (AMPs) are small, amphipathic molecules that interact with bacterial membranes, leading to membrane disruption and cell death. They are naturally produced in various organisms and play a crucial role in innate immunity. Despite their potential as antibiotics, few AMPs have reached the market due to stability and toxicity issues. This article reviews the development and clinical trials of AMPs, their therapeutic market, and modifications to improve their stability and bioavailability. The global growth of antibiotic resistance has driven research into new antimicrobial therapies, including AMPs. The article discusses the challenges and strategies for clinical application, such as resistance, chemical modifications, and toxicity. Despite these challenges, the interest in AMPs remains high due to their effectiveness against multi-resistant pathogens. The focus is now on improving their "druggability" through modifications and delivery systems.